Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy

Japanese Journal of Clinical Oncology

Volumn 38, Issue 2, 2008, Pages 129-133

  Hisasue, Shin Ichi ^a   Yanase, Masahiro ^a   Shindo, Tetsuya ^a   Iwaki, Hiroyuki ^a   Fukuta, Fumimasa ^b   Nishida, Sachiyo ^a   Muranaka, Takashi ^a   Miyamoto, Shintaro ^a   Tsukamoto, Taiji ^b   Takatsuka, Keiji ^a  

^a SUNAGAWA CITY MEDICAL CENTER   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biochemical recurrence; Body mass index; Multivariate analysis; PSA; Radical prostatectomy; Total testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; GLEASON SCORE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TESTOSTERONE BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; BODY MASS INDEX; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 40349094436     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym162     Document Type: Article

References (30)

1. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352(19):1977-84.
2. Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 1996;14(Suppl 2):12-20; discussion 21.
3. Kobayashi T, Mitsumori K, Nishizawa K, Kawahara T, Ogura K, Ide Y. Association between body mass index and prostate cancer detection rates in Japanese urologic patients. Urology 2005;66(1):130-4.
4. Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, et al. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer 2006;107(3):521-9.
5. Amling CL. Relationship between obesity and prostate cancer. Curr Opin Urol 2005;15(3):167-71.
6. Presti JC, Jr. Obesity and prostate cancer. Curr Opin Urol 2005;15(1):13-6.
7. Isom-Batz G, Bianco FJ, Jr., Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005;173(6):1935-7.
8. Lunenfeld BFOLS. Testosterone deficiency and the metabolic syndrome. Aging Male 2007;10(2):53-6.
9. Murai M. Summary and characteristics of 'General rule for clinical and pathological studies on prostate cancer (the 3rd edition)'. Nippon Rinsho 2002;60(Suppl 11):39-43.
10. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: Hypogonadism represents bad prognosis in prostate cancer. J Urol 2005;174(6):2178-80.
11. Walsh PC. Radical prostatectomy for the treatment of localized prostatic carcinoma. Urol Clin North Am 1980;7(3):583-91.
12. Freedland SJ, Terris MK, Platz EA, Presti JC, Jr. Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology 2005;66(1):108-13.
13. Buschemeyer WC, 3rd, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007;52(2):331-43.
14. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Jr., Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22(3):446-53.
15. Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 2005;174(3):919-22.
16. King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, et al. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: A report from the SEARCH database. Urology 2007;69(5):921-6.
17. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology 2005;66(5):1060-5.
18. Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol 2005;174(5):1798-801; discussion 1801.
19. Freedland SJ, Platz EA. Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data. Epidemiol Rev 2007;29:88-97.
20. Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ, et al. Leptin and prostate cancer. Prostate 2001;46(1):62-7.
21. Kaaks R, Lukanova A, Rinaldi S, Biessy C, Soderberg S, Olsson T, et al. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003;12(4):309-15.
22. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003;95(16):1240-4.
23. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: A case control study. Cancer Epidemiol Biomarkers Prev 2007;16(2):308-13.
24. Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005;47(3):308-12.
25. Palma D, Pickles T, Tyldesley S. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int 2007;100(2):315-9.
26. Morales A, Lunenfeld B. Investigation, treatment, monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002;5(2):74-86.
27. Inoue M, Sobue T, Tsugane S. Impact of body mass index on the risk of total cancer incidence and mortality among middle-aged Japanese: Data from a large-scale population-based cohort study - the JPHC study. Cancer Causes Control 2004;15(7):671-80.
28. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004;22(3):439-45.
29. Watanabe M, Nakayama T, Shiraishi T, Stemmermann GN, Yatani R. Comparative studies of prostate cancer in Japan versus the United States. A review. Urol Oncol 2000;5(6):274-83.
30. Cohen JH, Schoenbach VJ, Kaufman JS, Talcott JA, Schenck AP, Peacock S, et al. Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control 2006;17(6):803-11.